Chronic stress may weaken the cardiovascular benefits of LDL-C-lowering therapy and sustain inflammation in ASCVD. Learn more from EAS 2026.
The FDA has granted Coya 302 a fast-track designation for ALS, according to a press release from Coya Therapeutics. “ALS is a ...
COYA 302 is a proprietary biologic combination therapy that utilises a dual immunomodulatory approach.
Coya Therapeutics, Inc. (NASDAQ: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics ...
Skip breakfast, and within a few hours your body may be quietly pulling front-line immune cells off patrol and parking them ...
Vitamin D dips in winter as sunlight weakens, but a study of runners and non-runners found outdoor exercise helped protect levels naturally. Supplements supported immune balance, yet they did not ...
The FDA granted Fast Track designation to the investigational biologic combination therapy COYA 302 for amyotrophic lateral sclerosis treatment.
Patients who fasted during chemotherapy for ovarian cancer had significantly longer progression-free survival (PFS) compared ...
Fasting before and after chemotherapy may improve treatment response among women with high-grade serous ovarian cancer, ...
Professional antigen-presenting cells—monocytes and macrophages—engulf these proteins, digest them into short peptide ...
Imagine a routine blood draw at your annual physical that could warn you about depression before you ever feel it coming. That scenario is still years away from any doctor’s office, but a ...